Aldeyra Therapeutics, Inc.
ALDX
$2.19
$0.188.96%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -232.61% | -84.60% | -87.47% | 48.24% | 63.16% |
Total Depreciation and Amortization | -3.16% | -3.08% | -4.20% | -9.55% | -0.15% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 215.41% | 211.21% | -13.50% | -66.34% | -125.31% |
Change in Net Operating Assets | -51.57% | 648.12% | 134.60% | -283.85% | 562.66% |
Cash from Operations | -2,505.44% | 0.62% | 1.00% | -5.60% | 104.46% |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -201.26% | -100.00% |
Cash from Investing | -- | -- | -- | -201.26% | -100.00% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | 71.94% | -- | -- | -- | -- |
Issuance of Common Stock | 1,059.93% | -90.84% | -100.00% | -65.40% | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 100.77% | 37.49% | -100.00% | -65.40% | -- |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -2,555.38% | 65.11% | -135.63% | -295.70% | -103.25% |